

[illegible]

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

1

**Details of transactions requiring disclosure-**

Date of transaction:

25-Jul-16

Nature of transaction:

Units issued pursuant to Vital Healthcare Property Trust's rights issue

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$38,990,336.32

Number of financial products to which the transaction related:

18,745,354

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—*

Whether relevant interests were acquired or disposed of during a closed period:

N/A

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

N/A

Date of the prior written clearance (if any):

N/A

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

Ordinary units

Nature of relevant interest:

Paul Dalla Lana has a relevant interest in 99,806,501 ordinary units held by Deutsche Securities Australia Limited held on behalf of NWI Healthcare Properties LP as its custodian, and 3,292,950 ordinary units held by Deutsche Securities Australia Limited on behalf of NWI NZ Management Company Limited as its custodian

*For that relevant interest,-*

Number held in class:

103,099,451

Current registered holder(s):

Deutsche Securities Australia Limited

*For a derivative relevant interest,-*

Type of derivative:

N/A

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

N/A

A statement as to whether the derivative is cash settled or physically settled:

N/A

Maturity date of the derivative (if any):

N/A

Expiry date of the derivative (if any):

N/A

The price's specified terms (if any):

N/A

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A

*For that derivative relevant interest,-*

Parties to the derivative:

N/A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A

N/A

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

*Paul Dalla Lana*

Date of signature:

*26/7/16*

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

*Paul Dalla Lana*

|  |
|--|
|  |
|  |
|  |